迈向转移性肾细胞癌管理的共识:来自欧洲德尔菲研究的见解
该德尔菲研究于2023年5月至2024年4月由10个欧洲国家的14位专家完成两轮51项问卷,覆盖寡转移性肾细胞癌、转移性透明细胞肾细胞癌一线治疗及疗程、非透明细胞肾细胞癌治疗。首轮51项中12项(24%)达共识,研究结束时49项中25项(51%)达共识。
要点
- 79%专家将寡转移性肾细胞癌定义为转移灶≤5个,并认为通常不需立即全身治疗。
- 100%专家强调临床体能状态指导转移性透明细胞肾细胞癌治疗,86%认同国际泌尿病理学会分级和肉瘤样特征。
- 脑或骨转移患者分别有93%和86%认同纳武利尤单抗联合卡博替尼;肝转移患者对帕博利珠单抗联合仑伐替尼仅为一般一致。
核心结论
- 该德尔菲研究为转移性肾细胞癌管理提供见解,并强调多学科讨论对该棘手疾病的重要性。
研究设计与样本
- 德尔菲研究,2023年5月至2024年4月由10个欧洲国家的14位专家完成两轮51项问卷。
- 问卷覆盖四个主题:寡转移性肾细胞癌、转移性透明细胞肾细胞癌一线治疗、转移性透明细胞肾细胞癌治疗时长、非透明细胞肾细胞癌治疗。
- 一致性评分分为缺失/差(<50%)、一般(50-74%)、共识(≥75%)。
主要发现
- 首轮51项中12项(24%)达共识,研究结束时49项中25项(51%)达共识。
- 79%专家将寡转移性肾细胞癌定义为转移灶五个或更少,并同意通常不需立即全身治疗。
- 100%专家强调临床体能状态在指导转移性透明细胞肾细胞癌治疗中的重要性,86%同意国际泌尿病理学会分级和肉瘤样特征等额外因素。
- 脑转移和骨转移患者分别有93%和86%支持纳武利尤单抗联合卡博替尼,肝转移患者对帕博利珠单抗联合仑伐替尼为一般一致。
- 71%支持免疫检查点抑制剂在2年后停止,86%同意酪氨酸激酶抑制剂治疗时长未定义。
关键数值与推荐
- 共识阈值:一致性≥75%定义为共识,50-74%为一般,<50%为缺失/差。
- 寡转移性肾细胞癌定义:79%专家认同转移灶≤5个且通常不需立即全身治疗。
- 脑或骨转移:纳武利尤单抗联合卡博替尼获93%和86%支持;肝转移:帕博利珠单抗联合仑伐替尼为一般一致(50-74%)。
- 免疫检查点抑制剂停药:71%支持2年后停止;酪氨酸激酶抑制剂疗程:86%认同未定义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the definition, diagnosis, and first-line treatments for mRCC. METHODS: Between May 2023 and April 2024, 14 experts from ten European countries completed two Delphi rounds of a 51-item questionnaire covering four topics: (1) oligometastatic RCC; (2) first-line treatment for metastatic clear-cell RCC; (3) treatment duration for metastatic clear-cell RCC; and (4) treatment of non-clear-cell RCC. Agreement was scored as absent/poor (<50%), fair (50-74%), or consensus (≥75%). KEY FINDINGS AND LIMITATIONS: Consensus was reached for 12 of 51 items (24%) in the first round and 25 of 49 items (51%) by the study end. Notably, 79% of experts defined oligometastatic RCC as five or fewer metastases and agreed that it typically does not require immediate systemic treatment. All experts (100%) emphasized the importance of clinical performance status in guiding treatment for metastatic clear-cell RCC, with 86% agreeing on additional factors such as International Society of Urological Pathology grade and sarcomatoid features. Nivolumab plus cabozantinib was favored for patients with brain or bone metastases (93% and 86% agreement, respectively), while there was fair agreement on pembrolizumab plus lenvatinib for patients with liver metastases. In addition, 71% supported stopping immune checkpoint inhibitors after 2 yr, while 86% agreed on the undefined duration of tyrosine kinase inhibitor therapy. CONCLUSIONS AND CLINICAL IMPLICATIONS: This Delphi study offers insights into mRCC management, and highlights the importance of multidisciplinary discussions for this challenging disease.
引用
- Albiges L, Gross-Goupil M, Barthélémy P, et al. Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study. Eur Urol Oncol. 2025. PMID: 39924391. doi:10.1016/j.euo.2025.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。